1-20 of 29
Petra Langerbeins
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Clinical Trials & Observations
Moritz Fürstenau, Adam Giza, Jonathan Weiss, Fanni Kleinert, Sandra Robrecht, Fabian Franzen, Janina Stumpf, Petra Langerbeins, Othman Al-Sawaf, Florian Simon, Anna-Maria Fink, Christof Schneider, Eugen Tausch, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Kirsten Fischer, Karl-Anton Kreuzer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek, Paula Cramer
Journal: Blood
Blood (2024) 144 (3): 272–282.
https://doi.org/10.1182/blood.2023022730
Published: 2024
Includes: Supplemental data
Journal Articles

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

Clinical Trials & Observations
Petra Langerbeins, Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow, Othman Al-Sawaf, Anna Maria Fink, Moritz Fürstenau, Nadine Kutsch, Florian Simon, Valentin Goede, Manuela Hoechstetter, Carsten Utoft Niemann, Caspar da Cunha-Bang, Arnon Kater, Julie Dubois, Michael Gregor, Philipp Bernhard Staber, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Barbara Eichhorst, Kirsten Fischer, Michael Hallek
Journal: Blood
Blood (2024) 143 (25): 2588–2598.
https://doi.org/10.1182/blood.2023022564
Published: 2024
Includes: Supplemental data
Journal Articles

Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in Relapsed/Refractory CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag Trial

Moritz Furstenau, Adam Giza, Anna-Maria Fink, Sandra Robrecht, Jonathan Weiss, Fanni Kleinert, Christof Schneider, Eugen Tausch, Kirsten Fischer, Petra Langerbeins, Othman Al-Sawaf, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Karl-Anton Kreuzer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Stephan Stilgenbauer, Barbara F. Eichhorst, Michael Hallek, Paula Cramer
Journal: Blood
Blood (2023) 142 (Supplement 1): 203.
https://doi.org/10.1182/blood-2023-173708
Published: 2023
Journal Articles

MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study

Moritz Furstenau, Adam Giza, Christof Schneider, Eugen Tausch, Sandra Robrecht, Matthias Ritgen, Jörg Bittenbring, Holger F. Hebart, Björn Schöttker, Anna Lena Illert, Ullrich Graeven, Andrea Stoltefuss, Bernhard Heinrich, Robert Eckert, Anna-Maria Fink, Janina Stumpf, Florian Simon, Kirsten Fischer, Othman Al-Sawaf, Petra Langerbeins, Fanni Kleinert, Jonathan Weiss, Karl-Anton Kreuzer, Anke Schilhabel, Monika Brüggemann, Barbara F. Eichhorst, Stephan Stilgenbauer, Michael Hallek, Paula Cramer
Journal: Blood
Blood (2023) 142 (Supplement 1): 1897.
https://doi.org/10.1182/blood-2023-173707
Published: 2023
Journal Articles

IGLV3-21 R110 Is a Prognostic Marker for Early Stage CLL Patients Under Ibrutinib Treatment or Watch & Wait: Results from the Double-Blind, Randomized, Placebo-Controlled GCLLSG CLL12 Trial

Deyan Y. Yosifov, Sandra Robrecht, Adam Giza, Armin Riecke, Christof Schneider, Billy Jebaraj, Hassan Jumaa, Marc Young, Lothar Müller, Ursula Vehling-Kaiser, Michael J. Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna-Maria Fink, Kirsten Fischer, Barbara F. Eichhorst, Michael Hallek, Petra Langerbeins, Stephan Stilgenbauer, Eugen Tausch
Journal: Blood
Blood (2023) 142 (Supplement 1): 1903.
https://doi.org/10.1182/blood-2023-179767
Published: 2023
Journal Articles

Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group

Florian Simon, Rudy Ligtvoet, Sandra Robrecht, Paula Cramer, Nadine Kutsch, Moritz Furstenau, Valentin Goede, Julia Von Tresckow, Petra Langerbeins, Anna-Maria Fink, Henriette Huber, Eugen Tausch, Christof Schneider, Clemens-Martin Wendtner, Matthias Ritgen, Martin Dreyling, Lothar Müller, Lutz Jacobasch, Werner Heinz, Ursula Vehling-Kaiser, Liliya Sivcheva, Sebastian Böttcher, Peter Dreger, Thomas Illmer, Michael Gregor, Philipp Bernhard Staber, Stephan Stilgenbauer, Carsten Utoft Niemann, Arnon P. Kater, Kirsten Fischer, Barbara F. Eichhorst, Michael Hallek, Othman Al-Sawaf
Journal: Blood
Blood (2023) 142 (Supplement 1): 1901.
https://doi.org/10.1182/blood-2023-178597
Published: 2023
Journal Articles

Outcomes and Treatment Sequences of Therapies with BCL2- and BTK Inhibitors in Chronic Lymphocytic Leukemia (CLL): An Analysis of Patient Data within the German CLL Study Group (GCLLSG) Registry

Nadine Kutsch, Rudy Ligtvoet, Sandra Robrecht, Hartmut Linde, Thomas Illmer, Steffen Doerfel, Joerg Lipke, Ali Aldaoud, Rudolf Schlag, Jolanta Dengler, Othman Al-Sawaf, Petra Langerbeins, Paula Cramer, Barbara F. Eichhorst, Michael Hallek, Kirsten Fischer, Anna Maria Fink
Journal: Blood
Blood (2023) 142 (Supplement 1): 4644.
https://doi.org/10.1182/blood-2023-185741
Published: 2023
Journal Articles

Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial

Armin Riecke, Eugen Tausch, Deyan Y. Yosifov, Christof Schneider, Sandra Robrecht, Adam Giza, Lothar Müller, Ursula Vehling-Kaiser, Michael J. Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna-Maria Fink, Barbara F. Eichhorst, Kirsten Fischer, Michael Hallek, Petra Langerbeins, Stephan Stilgenbauer
Journal: Blood
Blood (2023) 142 (Supplement 1): 199.
https://doi.org/10.1182/blood-2023-180558
Published: 2023
Journal Articles

A Phase 1 Study Evaluating PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Select Relapsed/Refractory B-Cell Malignancies

Bruce D. Cheson, Geoffrey P. Shouse, Sarit Assouline, Katharine L. Lewis, Eliza A Hawkes, Talha Munir, Andrew S. Davies, Petra Langerbeins, Constantine S. Tam, Gareth P. Gregory, Michael Y. Choi, William Sun, Siminder K. Atwal, Wan-Jen Hong, Clémentine Sarkozy
Journal: Blood
Blood (2023) 142 (Supplement 1): 6324.
https://doi.org/10.1182/blood-2023-182434
Published: 2023
Journal Articles

Cardiotoxicity in patients treated with acalabrutinib

Petra Langerbeins
Journal: Blood
Blood (2022) 140 (20): 2096–2097.
https://doi.org/10.1182/blood.2022017791
Published: 2022
Journal Articles

COVID-19 in patients with hematologic malignancy

Petra Langerbeins, Michael Hallek
Journal: Blood
Blood (2022) 140 (3): 236–252.
https://doi.org/10.1182/blood.2021012251
Published: 2022
Journal Articles

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

Clinical Trials & Observations
Petra Langerbeins, Can Zhang, Sandra Robrecht, Paula Cramer, Moritz Fürstenau, Othman Al-Sawaf, Julia von Tresckow, Anna-Maria Fink, Karl-Anton Kreuzer, Ursula Vehling-Kaiser, Eugen Tausch, Lothar Müller, Michael Josef Eckart, Rudolf Schlag, Werner Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Stauch, Clemens-Martin Wendtner, Kirsten Fischer, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Journal: Blood
Blood (2022) 139 (2): 177–187.
https://doi.org/10.1182/blood.2021010845
Published: 2022
Includes: Supplemental data
Journal Articles

Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations

Clinical Trials & Observations
Paula Cramer, Eugen Tausch, Julia von Tresckow, Adam Giza, Sandra Robrecht, Christof Schneider, Moritz Fürstenau, Petra Langerbeins, Othman Al-Sawaf, Benedikt W. Pelzer, Anna Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Barbara Eichhorst, Michael Kneba, Stephan Stilgenbauer, Michael Hallek
Journal: Blood
Blood (2021) 138 (19): 1805–1816.
https://doi.org/10.1182/blood.2020010484
Published: 2021
Includes: Supplemental data
Journal Articles

Severe Infections in Patients with Chronic Lymphocytic Leukemia Treated with (Immuno-)Chemotherapy: A Pooled Analysis of Gcllsg Trials

Othman Al-Sawaf, MD, Can Zhang, PhD, Sandra Robrecht, PhD, Anna-Maria Fink, MD, Paula Cramer, Carmen D. Herling, MD PhD, Julia Von Tresckow, MD, Elisabeth Lange, MD, Sebastian Böttcher, MD PhD, Michael G. Kiehl, MD PhD, Martin Dreyling, MD, Ulrich Jaeger, Michael Gregor, MD, Ursula Vehling-Kaiser, MD, Matthias Ritgen, MD, Jan Dürig, MD, Eugen Tausch, MD, Stephan Stilgenbauer, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Valentin Goede, MD, Michael Hallek, MD, Barbara Eichhorst, MD, Petra Langerbeins, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-139242
Published: 2020
Journal Articles

Bendamustine Followed By Obinutuzumab and Idelalisib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BCG Trial of the German CLL Study Group (GCLLSG)

Paula Cramer, Julia Von Tresckow, MD, Anna-Maria Fink, MD, Gracia Braun, Sandra Robrecht, PhD, Can Zhang, PhD, Eugen Tausch, MD, Lothar Müller, MD, Wolfgang Knauf, MD, Othman Al-Sawaf, MD, Benedikt Pelzer, MD, Petra Langerbeins, MD, Kirsten Fischer, MD, Karl-Anton Kreuzer, MD, Matthias Ritgen, MD, Michael Kneba, MDPhD, Clemens-Martin Wendtner, MD, Stephan Stilgenbauer, MD, Barbara Eichhorst, MD, Michael Hallek, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–23.
https://doi.org/10.1182/blood-2020-134827
Published: 2020
Journal Articles

International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia

Adalgisa Condoluci, Lodovico Terzi di Bergamo, Petra Langerbeins, Manuela A. Hoechstetter, Carmen D. Herling, Lorenzo De Paoli, Julio Delgado, Kari G. Rabe, Massimo Gentile, Michael Doubek, Francesca R. Mauro, Giorgia Chiodin, Mattias Mattsson, Jasmin Bahlo, Giovanna Cutrona, Jana Kotaskova, Clara Deambrogi, Karin E. Smedby, Valeria Spina, Alessio Bruscaggin, Wei Wu, Riccardo Moia, Elena Bianchi, Bernhard Gerber, Emanuele Zucca, Silke Gillessen, Michele Ghielmini, Franco Cavalli, Georg Stussi, Mark A. Hess, Tycho S. Baumann, Antonino Neri, Manlio Ferrarini, Richard Rosenquist, Francesco Forconi, Robin Foà, Sarka Pospisilova, Fortunato Morabito, Stephan Stilgenbauer, Hartmut Döhner, Sameer A. Parikh, William G. Wierda, Emili Montserrat, Gianluca Gaidano, Michael Hallek, Davide Rossi
Journal: Blood
Blood (2020) 135 (21): 1859–1869.
https://doi.org/10.1182/blood.2019003453
Published: 2020
Includes: Supplemental data
Journal Articles

Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG)

Julia Von Tresckow, Paula Cramer, Nisha De Silva, MBBS, MRCP, FRCPath, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Petra Langerbeins, MD, Anna- Maria Fink, MD, Othman Al-Sawaf, MD, Moritz Fürstenau, MD, Thomas Illmer, MD, Holger Klaproth, Eugen Tausch, Matthias Ritgen, Kirsten Fischer, MD, Clemens-Martin Wendtner, Karl-Anton Kreuzer, MD, Stephan Stilgenbauer, MD, Sebastian Böttcher, MD, Barbara F. Eichhorst, MD, Michael Hallek, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3046.
https://doi.org/10.1182/blood-2019-125895
Published: 2019
Journal Articles

Durable Remissions after Discontinuation of Combined Targeted Treatment in Patients with Chronic Lymphocytic Leukemia (CLL) Harbouring a High-Risk Genetic Lesion (del(17p)/TP53 Mutation)

Paula Cramer, Julia von Tresckow, MD, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Eugen Tausch, MD, Moritz Fürstenau, MD, Petra Langerbeins, MD, Othman Al-Sawaf, MD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Clemens-Martin Wendtner, Barbara Eichhorst, Michael Kneba, Stephan Stilgenbauer, MD PhD, Michael Hallek
Journal: Blood
Blood (2018) 132 (Supplement 1): 694.
https://doi.org/10.1182/blood-2018-99-113155
Published: 2018
Journal Articles

Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG)

Moritz Fürstenau, MD, Georg Hopfinger, MD, Sandra Robrecht, PhD, Anna-Maria Fink, MD, Othman Al-Sawaf, MD, Petra Langerbeins, MD, Paula Cramer, Julia Von Tresckow, MD, Christian Maurer, MD, Nadine Kutsch, MD, Manuela Hoechstetter, MD, Martin Dreyling, MD PhD, Elisabeth Lange, Michael Kneba, Stephan Stilgenbauer, MD PhD, Hartmut Döhner, MD, Manfred Hensel, MD, Michael G. Kiehl, MD PhD, Ulrich Jaeger, MD, Clemens-Martin Wendtner, Valentin Goede, MD, Kirsten Fischer, MD, Michael Hallek, Barbara Eichhorst, Sebastian Theurich, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4429.
https://doi.org/10.1182/blood-2018-99-113257
Published: 2018
Journal Articles

Bendamustine Followed By Ofatumumab and Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BIO Trial of the German CLL Study Group (GCLLSG)

Paula Cramer, MD, Julia von Tresckow, MD, Sandra Robrecht, PhD, Jasmin Bahlo, PhD, Othman Al-Sawaf, MD, Petra Langerbeins, MD, Werner Heinz, MD, Ursula Vehling-Kaiser, MD, Jan Dürig, MD, Eugen Tausch, MD, Manfred Hensel, MD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Karl-Anton Kreuzer, MD, Sebastian Böttcher, MD PhD, Matthias Ritgen, Michael Kneba, MD, Clemens-Martin Wendtner, MD, Stephan Stilgenbauer, MD PhD, Barbara F. Eichhorst, MD, Michael J. Hallek, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 494.
https://doi.org/10.1182/blood.V130.Suppl_1.494.494
Published: 2017